Botanix Pharmaceuticals logo

Botanix Pharmaceuticals(OTC) BXPHF

Market Cap$44.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-92%
5 Year-71%
1 Year-85%
1 Month-5%
$0.02
+0.00%
+0.00Today
Botanix Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 0.022026-09-30
Botanix Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+46.79%USD 0.012026-09-21
1 month-4.76%USD 0.022026-08-18
3 month+40.35%USD 0.012026-07-01
Year to date-79.81%USD 0.082025-12-29
1 year-84.99%USD 0.112025-09-30
3 year-94.67%USD 0.302023-09-29
5 year-71.38%USD 0.062021-09-21
Since inception-92%USD 0.202019-09-09

Botanix Pharmaceuticals Financials at a Glance

Market Cap

$44.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$40.27M

Net Income (TTM)

-A$156.10M

EPS (TTM)

-$0.02

P/E Ratio

-0.73

Dividend

$0.00

Beta (Volatility)

0.20 (Low)

Price

$0.02

Volume

15,000

Open

$0.02

Previous Close

$0.02

Daily Range

$0.02 - $0.02

52-Week Range

$0.01 - $0.11

Estimated Earnings Date

Mar 3, 2027

BXPHF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Botanix Pharmaceuticals

Botanix Pharmaceuticals Limited is a biotechnology company specializing in dermatology, focusing on developing safe and effective topical treatments for serious skin conditions. The company’s product pipeline includes treatments for moderate to severe acne, atopic dermatitis, rosacea, and axillary hyperhidrosis, utilizing a proprietary drug delivery system.

Products and Services
  • Topical treatments for moderate to severe acne
  • Innovative solutions for atopic dermatitis and rosacea
  • Exclusive drug delivery system for skin diseases
Growth Outlook
  • Strong market demand for dermatological treatments is expected to drive growth
  • Recent product advancements may enhance competitive positioning
  • Potential for strategic partnerships to expand market reach
Financial Highlights
  • Recent quarterly revenue of 17,981,841 AUD shows significant growth
  • Cash and cash equivalents reached 36,579,890 AUD, providing operational stability
  • Current ratio of 2.59 indicates strong liquidity position
Botanix Pharmaceuticals Limited is positioned in a growing market with a focus on innovative dermatological solutions. The company’s recent financial performance indicates a positive trajectory, with substantial revenue growth and a solid liquidity position. The proprietary drug delivery system offers a competitive edge, while the potential for strategic partnerships could further enhance market presence. Investors may find the company's focus on serious skin conditions appealing, given the increasing demand for effective dermatological treatments.
AI Generated • Sep 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

33

CEO

Howie McKibbon, PharmD

Website

www.botanixpharma.com

Headquarters

Melbourne, VIC 3008, AU

BXPHF Financials

Key Financial Metrics (TTM)

Gross Margin

-172.20%

Operating Margin

-200.82%

Net Income Margin

-202.15%

Return on Equity

-118.74%

Return on Capital

-88.56%

Return on Assets

-65.83%

Earnings Yield

-1.37%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$44.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.76B

Volume

15.00K

Avg. Volume

15.77K

Financials (TTM)

Gross Profit

-A$57.36M

Operating Income

-A$150.04M

EBITDA

-A$148.60M

Operating Cash Flow

-A$143.12M

Capital Expenditure

-A$286.43K

Free Cash Flow

-A$143.41M

Cash & ST Invst.

A$36.58M

Total Debt

A$14.72M

Botanix Pharmaceuticals Performance Analysis

Botanix Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 615,506N/A
20242024-06-30AUD 678,02310.2%
20252025-06-30AUD 4,198,478519.2%
20262026-06-30AUD 23,386,731457.0%
Botanix Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-77.7%
Q42025-06-301333.2%
Q22025-12-31204.9%
Q42026-06-309.0%
Botanix Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-45.9%
20242024-06-30AUD -0.0115.1%
20252025-06-30AUD -0.03396.7%
20262026-06-30AUD -0.02-28.1%
Botanix Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-214.8%
Q42025-06-30-74.1%
Q22025-12-3142.9%
Q42026-06-309.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$17.98M

+963.0%

Gross Profit

-A$30.63M

-3017.5%

Gross Margin

-1.70%

N/A

Market Cap

$44.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.02M

N/A

Employees

11

N/A

Net Income

-A$36.52M

-334.7%

EBITDA

-A$35.64M

-324.2%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$36.58M

-53.9%

Total Debt

A$14.72M

N/A

Accounts Receivable

A$6.63M

+711.7%

Inventory

A$31.31M

+2488.6%

Long Term Debt

A$448.03K

N/A

Short Term Debt

A$14.27M

N/A

Return on Assets

-65.83%

N/A

Return on Invested Capital

-92.42%

N/A

Free Cash Flow

-A$31.91M

-618.1%

Operating Cash Flow

-A$31.91M

-630.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NDTPNDT Pharmaceuticals Inc.
$0.40+13.43%
JWCTFJW (Cayman) Therapeutics Co. Ltd
$0.20+0.00%
AAWHAscend Wellness Holdings, Inc.
$0.43+0.70%
IPHYFInnate Pharma S.A.
$1.51+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About BXPHF

What is the current price of Botanix Pharmaceuticals?

Botanix Pharmaceuticals is trading at $0.02 per share.

What is the 52-week range for Botanix Pharmaceuticals?

Over the past 52 weeks, Botanix Pharmaceuticals has traded between $0.01 and $0.11.

How much debt does Botanix Pharmaceuticals have?

As of the most recent reporting period, Botanix Pharmaceuticals reported total debt of A$17.85M.

How much cash does Botanix Pharmaceuticals have on hand?

Botanix Pharmaceuticals reported A$25.38M in cash and cash equivalents in its most recent financial results.

What is Botanix Pharmaceuticals’s dividend yield?

Botanix Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services